FDA Approval Gives More Lung Cancer Patients Immunotherapy Option

Late last week, the U.S. Food and Drug Administration (FDA) announced that it had approved the use of the immunotherapeutic agent nivolumab (Opdivo) for treating patients with metastatic, nonsquamous non-small …

Read More

FDA Approves First Immunotherapy-Companion Diagnostic Combo for Lung Cancer

On the heels of the U.S. Food and Drug Administration’s approval of a combination of immune checkpoint inhibitors for unresectable and metastatic melanoma comes yet another immunotherapy approval. This time …

Read More

New Immunotherapy Advances Presented at the AACR Annual Meeting 2015

Immunotherapeutics called PD-1 inhibitors have garnered a lot of attention in the past year thanks to exciting clinical trial results that led to U.S. Food and Drug Administration (FDA) approvals …

Read More